Multidrug-resistant TB in Zambia: review of national data from 2000 to 2011.

نویسندگان

  • Nathan Kapata
  • Pascalina Chanda-Kapata
  • Matthew Bates
  • Peter Mwaba
  • Frank Cobelens
  • Martin P Grobusch
  • Alimuddin Zumla
چکیده

BACKGROUND Multidrug-resistant tuberculosis (MDR-TB) is posing a great threat to global TB control. The burden in Zambia is not well defined because routine surveillance data are scarce. We reviewed national MDR-TB data for the last decade to inform future public health policy with respect to MDR-TB in Zambia. METHOD Retrospective review of national surveillance of MDR-TB data, TB programme and laboratory reports between 2000 and 2011. RESULTS The total number of DSTs performed during this 11-year period was 2,038 and accounted for 2.6% (2,038/78,639) of all the retreatment cases notified. The total number of diagnosed MDR-TB cases for this period was 446, of which 56.3% (251/446) were male and 41.7% (186/446) female. Only one child was found to have MDR-TB. Poly-drug resistance accounted for 18.9% (172/911) of the DR-TB cases and 8.4% of the total DSTs. 8.8% (80/911) of the DR-TB cases showed either rifampicin mono- or poly-resistance other than MDR-TB. No XDR-TB was reported. There were no data available on DR-TB and HIV co-infection. Only 65 MDR-TB patients were notified and put on second-line treatment according to WHO guidelines. CONCLUSIONS Multidrug-resistant tuberculosis may be an emerging challenge in Zambia. There is a need to invest in improving the capacity of the TB programme to detect and manage MDR-TB.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The Incidence of Amikacin Ototoxicity in Multidrug-Resistant Tuberculosis Patients

Amikacin has been shown to irreversibly suppressCochlear activity.The aim of this study is to assess the incidence of amikacinototoxicity in multidrug-resistant tuberculosis patients and riskfactors associated withthis ototoxicity.In this cross-sectional study, 41 patientswith multidrug-resistant tuberculosis (MDR-TB) were included.All patients received fixed dose of intravenous amikacin(500 mg...

متن کامل

The Incidence of Amikacin Ototoxicity in Multidrug-Resistant Tuberculosis Patients

Amikacin has been shown to irreversibly suppressCochlear activity.The aim of this study is to assess the incidence of amikacinototoxicity in multidrug-resistant tuberculosis patients and riskfactors associated withthis ototoxicity.In this cross-sectional study, 41 patientswith multidrug-resistant tuberculosis (MDR-TB) were included.All patients received fixed dose of intravenous amikacin(500 mg...

متن کامل

IL-10 and IL-12 Production in Response to Mycobacterium Tuberculosis Total Lipid Antigens in Multidrug-Resistant Tuberculosis

Background: Mycobacterium tuberculosis lipid antigens take part in pathogenicity of the bacterium but the response of monocytes/macrophages to these antigens in tubercu-losis is not well known. Objective: The aim of current investigation was to study the M. tuberculosis lipid antigens in tuberculosis pathogenesis. Methods: In the present study M. tuberculosis lipid antigens were extracted. Mono...

متن کامل

Nanomedicine for tuberculosis: Insights from animal models

Patient noncompliance to current tuberculosis (TB) therapy owing to multidrug administration daily leads to treatment failure and emergence of multidrug resistant and extensively drug resistant TB. To avoid the daily dosing, application of nanotechnology is the only viable solution by virtue of sustained release of drugs. Other potential advantages of the system include the possibility of selec...

متن کامل

What Can We Learn About the Processes of Regulation of Tuberculosis Medicines From the Experiences of Health Policy and System Actors in India, Tanzania, and Zambia?

Background The unregulated availability and irrational use of tuberculosis (TB) medicines is a major issue of public health concern globally. Governments of many low- and middle-income countries (LMICs) have committed to regulating the quality and availability of TB medicines, but with variable success. Regulation of TB medicines remains an intractable challenge in many settings, but the reason...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Tropical medicine & international health : TM & IH

دوره 18 11  شماره 

صفحات  -

تاریخ انتشار 2013